Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
MK-677 (Ibutamoren) vs Somatrogon (Ngenla)
An educational, source-based comparison of MK-677 (Ibutamoren) and Somatrogon (Ngenla) — how each peptide works, what it's researched for, and what to know before going deeper.
Orally bioavailable non-peptide ghrelin mimetic.
Technically a small-molecule ghrelin receptor agonist (not a peptide), often grouped with peptide GH research. Orally bioavailable, it elevates GH and IGF-1 over 24 hours and increases appetite.
- GH/IGF-1 elevation in adults
- Lean mass and bone density in elderly
- Sleep quality (slow-wave sleep)
- • Not FDA-approved.
- • Insulin resistance and fluid retention reported.
- • Banned by WADA.
Long-acting recombinant human growth hormone for pediatric GH deficiency — weekly dosing.
A long-acting recombinant fusion protein of human growth hormone with three copies of the C-terminal peptide (CTP) of hCG beta-subunit, extending half-life and enabling once-weekly subcutaneous dosing instead of daily.
- Pediatric growth hormone deficiency
- • FDA-approved June 2023.
- • Same class warnings as daily GH (intracranial hypertension, glucose effects, scoliosis progression).
- • Injection-site reactions common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| MK-677 (Ibutamoren) | MK-677 increases GH and IGF-1 in elderly adults | Annals of Internal Medicine | 2008 | Two-year RCT showing sustained IGF-1 elevation and lean mass increase. |
| Somatrogon (Ngenla) | Phase 3 weekly somatrogon vs daily somatropin in children with GHD | JCEM | 2022 | Non-inferior annual height velocity at 12 months with significantly better treatment-burden scores. |
Side-effect & safety grid
- Not FDA-approved.
- Insulin resistance and fluid retention reported.
- Banned by WADA.
- FDA-approved June 2023.
- Same class warnings as daily GH (intracranial hypertension, glucose effects, scoliosis progression).
- Injection-site reactions common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
MK-677 (Ibutamoren) vs Somatrogon (Ngenla) — Key differences
- Class: MK-677 (Ibutamoren) is classified as Growth Hormone Axis · Small Molecule, while Somatrogon (Ngenla) is GH Analog · Endocrine.
- Primary research focus: MK-677 (Ibutamoren) — gh/igf-1 elevation in adults; Somatrogon (Ngenla) — pediatric growth hormone deficiency.
- Tag: Growth hormone · Oral vs FDA-Approved · Endocrine.